What is the clinical evidence from this study?

Study design: Other. Intervention: Serotonin and serotonin antagonists (Promethazine, LSD-25, 2-brom derivative). Primary outcome: Pulmonary vasoconstriction and bronchomotor tone.

What question did this study set out to answer?

To evaluate the pulmonary vasoconstrictor potency of serotonin and assess the blocking efficacy of selected serotonin antagonists within an isolated pulmonary vascular preparation.

May 1, 1958Circulation Research

Pulmonary Vascular Responses to Serotonin and Effects of Certain Serotonin Antagonists

View Full Paper

Ask AI

Bookmark

Key result

Serotonin was a potent pulmonary vasoconstrictor in an experimental preparation, and its effects were potently blocked by promethazine, LSD-25, and its 2-brom derivative.

Population

Experimental preparation in which drugs injected into the pulmonary artery are temporarily excluded from the…

Design

Preclinical

Authors

JRJohn C. RoseStanford University ETERIC J. TAZAROGeorgetown University Medical Center

Discussion

Member takes

Implication

Hypothesis-generating for serotonin blockade in pulmonary vascular models; leaves open clinical translation.

Key Points

To evaluate the pulmonary vasoconstrictor potency of serotonin and assess the blocking efficacy of selected serotonin antagonists within an isolated pulmonary vascular preparation.
Utilized an experimental preparation where agents administered directly into the pulmonary artery were temporarily excluded from systemic circulation.
Assessed changes in pulmonary vascular response and bronchomotor tone following serotonin injection, comparing airway effects directly to acetylcholine.
Tested the inhibitory effects of promethazine, LSD-25, and its 2-brom derivative against serotonin-mediated pulmonary responses.
Serotonin exhibited the highest pulmonary vasoconstrictor potency among the studied drugs, while producing minimal alterations in bronchomotor tone compared to acetylcholine.
Pulmonary arterial administration of serotonin produced no concomitant systemic vascular changes or cardiac reflexes.
Promethazine, LSD-25, and 2-brom-LSD acted as potent antagonists, effectively blocking serotonin-induced vascular actions in the pulmonary bed.

Structured PICO

Population

Experimental preparation in which drugs injected into the pulmonary artery are temporarily excluded from the systemic circulation

Intervention

Serotonin, promethazine, LSD-25, and its 2-brom derivative

Outcome

Pulmonary vasoconstriction and blockade of serotonin effectssurrogate

Serotonin acts as a potent pulmonary vasoconstrictor in an experimental model, an effect that can be blocked by promethazine and LSD derivatives.

Cite This Study

Rose et al. (1958) studied this question. Serotonin and serotonin antagonists (Promethazine, LSD-25, 2-brom derivative) was evaluated on Pulmonary vasoconstriction and bronchomotor tone. Serotonin was a potent pulmonary vasoconstrictor in an experimental preparation, and its effects were potently blocked by promethazine, LSD-25, and its 2-brom derivative.

synapsesocial.com/papers/6aa2cde8da8566d019e56d65 https://doi.org/10.1161/01.res.6.3.283

View Full Paper

Ask AI

Bookmark

Pulmonary Vascular Responses to Serotonin and Effects of Certain Serotonin Antagonists

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Pulmonary Vascular Responses to Serotonin and Effects of Certain Serotonin Antagonists

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider